Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Vorinostat.
Acenocoumarol
Vorinostat may increase the anticoagulant activities of Acenocoumarol.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Vorinostat.
Advertisement
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Vorinostat.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Vorinostat.
Amiodarone
Vorinostat may increase the QTc-prolonging activities of Amiodarone.
Advertisement
Anagrelide
Vorinostat may increase the QTc-prolonging activities of Anagrelide.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Vorinostat.
Arsenic Trioxide
Vorinostat may increase the QTc-prolonging activities of Arsenic trioxide.
Advertisement
Artemether
Vorinostat may increase the QTc-prolonging activities of Artemether.
Asenapine
Vorinostat may increase the QTc-prolonging activities of Asenapine.
Azithromycin
Vorinostat may increase the QTc-prolonging activities of Azithromycin.
Bedaquiline
Vorinostat may increase the QTc-prolonging activities of Bedaquiline.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Vorinostat.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Vorinostat.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vorinostat.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.
Ceritinib
Vorinostat may increase the QTc-prolonging activities of Ceritinib.
Chloroquine
Vorinostat may increase the QTc-prolonging activities of Chloroquine.
Chlorpromazine
Vorinostat may increase the QTc-prolonging activities of Chlorpromazine.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Vorinostat.
Ciprofloxacin
Vorinostat may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Vorinostat may increase the QTc-prolonging activities of Cisapride.
Citalopram
Vorinostat may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Vorinostat may increase the QTc-prolonging activities of Clarithromycin.
Clozapine
The risk or severity of adverse effects can be increased when Vorinostat is combined with Clozapine.
Crizotinib
Vorinostat may increase the QTc-prolonging activities of Crizotinib.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Vorinostat.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Vorinostat.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Vorinostat.
Dicumarol
Vorinostat may increase the anticoagulant activities of Dicoumarol.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Vorinostat.
Digoxin
Digoxin may decrease the cardiotoxic activities of Vorinostat.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Vorinostat.
Disopyramide
Vorinostat may increase the QTc-prolonging activities of Disopyramide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.
Dofetilide
Vorinostat may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Vorinostat may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Vorinostat may increase the QTc-prolonging activities of Domperidone.
Dronedarone
Vorinostat may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Vorinostat may increase the QTc-prolonging activities of Droperidol.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Vorinostat.
Eliglustat
Vorinostat may increase the QTc-prolonging activities of Eliglustat.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.
Erythromycin
Vorinostat may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Vorinostat may increase the QTc-prolonging activities of Escitalopram.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Vorinostat.
Flecainide
Vorinostat may increase the QTc-prolonging activities of Flecainide.
Fluindione
Vorinostat may increase the anticoagulant activities of Fluindione.
Fluoxetine
Vorinostat may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Vorinostat may increase the QTc-prolonging activities of Flupentixol.
Gadobenate
Vorinostat may increase the QTc-prolonging activities of Gadobenic acid.
Gemifloxacin
Vorinostat may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Vorinostat may increase the QTc-prolonging activities of Gemifloxacin.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Vorinostat.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Vorinostat.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Vorinostat.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Vorinostat.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Vorinostat.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Vorinostat.
Goserelin
Vorinostat may increase the QTc-prolonging activities of Goserelin.
Granisetron
Vorinostat may increase the QTc-prolonging activities of Granisetron.
Haloperidol
Vorinostat may increase the QTc-prolonging activities of Haloperidol.
Ibutilide
Vorinostat may increase the QTc-prolonging activities of Ibutilide.
Iloperidone
Vorinostat may increase the QTc-prolonging activities of Iloperidone.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Vorinostat.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Vorinostat.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Vorinostat.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Vorinostat.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Vorinostat.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Vorinostat.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Vorinostat.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Vorinostat.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Vorinostat.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Vorinostat.
Lenvatinib
Vorinostat may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Vorinostat may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Vorinostat may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Vorinostat may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Vorinostat may increase the QTc-prolonging activities of Levofloxacin.
Linagliptin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Vorinostat.
Lipegfilgrastim
Vorinostat may increase the myelosuppressive activities of Lipegfilgrastim.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Vorinostat.
Lopinavir
Vorinostat may increase the QTc-prolonging activities of Lopinavir.
Lumefantrine
Vorinostat may increase the QTc-prolonging activities of Lumefantrine.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.
Methadone
Vorinostat may increase the QTc-prolonging activities of Methadone.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Vorinostat.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Vorinostat.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Vorinostat.
Moxifloxacin
Vorinostat may increase the QTc-prolonging activities of Moxifloxacin.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Vorinostat.
Nilotinib
Vorinostat may increase the QTc-prolonging activities of Nilotinib.
Ofloxacin
Vorinostat may increase the QTc-prolonging activities of Ofloxacin.
Ondansetron
Vorinostat may increase the QTc-prolonging activities of Ondansetron.
Ouabain
Ouabain may decrease the cardiotoxic activities of Vorinostat.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vorinostat.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorinostat.
Paliperidone
Vorinostat may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
Vorinostat may increase the QTc-prolonging activities of Panobinostat.
Pazopanib
Vorinostat may increase the QTc-prolonging activities of Pazopanib.
Pentamidine
Vorinostat may increase the QTc-prolonging activities of Pentamidine.
Perflutren
Vorinostat may increase the QTc-prolonging activities of Perflutren.
Phenformin
The therapeutic efficacy of Phenformin can be decreased when used in combination with Vorinostat.
Phenindione
Vorinostat may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Vorinostat may increase the anticoagulant activities of Phenprocoumon.
Pimozide
Vorinostat may increase the QTc-prolonging activities of Pimozide.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Vorinostat.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Vorinostat.
Primaquine
Vorinostat may increase the QTc-prolonging activities of Primaquine.
Procainamide
Vorinostat may increase the QTc-prolonging activities of Procainamide.
Promazine
Vorinostat may increase the QTc-prolonging activities of Promazine.
Propafenone
Vorinostat may increase the QTc-prolonging activities of Propafenone.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Vorinostat.
Quetiapine
Vorinostat may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Vorinostat may increase the QTc-prolonging activities of Quetiapine.
Quinidine
Vorinostat may increase the QTc-prolonging activities of Quinidine.
Quinine
Vorinostat may increase the QTc-prolonging activities of Quinine.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Vorinostat.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Vorinostat.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Vorinostat.
Saquinavir
Vorinostat may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Vorinostat may increase the QTc-prolonging activities of Saquinavir.
Saxagliptin
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Vorinostat.
Saxagliptin Anhydrous
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Vorinostat.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Vorinostat.
Sitagliptin Phosphate
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Vorinostat.
Sotalol
Vorinostat may increase the QTc-prolonging activities of Sotalol.
Sulfisoxazole
Vorinostat may increase the QTc-prolonging activities of Sulfisoxazole.
Telavancin
Vorinostat may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Vorinostat may increase the QTc-prolonging activities of Telithromycin.
Tetrabenazine
Vorinostat may increase the QTc-prolonging activities of Tetrabenazine.
Thioridazine
Vorinostat may increase the QTc-prolonging activities of Thioridazine.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Vorinostat.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Vorinostat.
Toremifene
Vorinostat may increase the QTc-prolonging activities of Toremifene.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Vorinostat.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Vorinostat.
Valproate
Valproic Acid may increase the thrombocytopenic activities of Vorinostat.
Valproic Acid
Valproic Acid may increase the thrombocytopenic activities of Vorinostat.
Vandetanib
Vorinostat may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Vorinostat.
Vildagliptin
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Vorinostat.
Warfarin
Vorinostat may increase the anticoagulant activities of Warfarin.
Ziprasidone
Vorinostat may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Vorinostat may increase the QTc-prolonging activities of Zuclopenthixol.
